石药集团宣布,其研发的注射用紫杉醇蛋白结合颗粒混悬液(白蛋白结合型)已获得快速审评资格,受理号为Syhx2011g1。这一进展标志着该创新药物在审批流程上迈出关键一步,有望加速其上市进程,为相关疾病治疗提供新选择。
石药集团宣布,其研发的注射用紫杉醇蛋白结合颗粒混悬液(白蛋白结合型)已获得快速审评资格,受理号为Syhx2011g1。这一进展标志着该创新药物在审批流程上迈出关键一步,有望加速其上市进程,为相关疾病治疗提供新选择。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.